Please use this identifier to cite or link to this item: https://repository.monashhealth.org/monashhealthjspui/handle/1/32693
Title: Low blood selenium concentrations in schizophrenic patients on clozapine.
Authors: Vaddadi G.;Vaddadi K.S.;Soosai E.
Institution: (Vaddadi) Department of Psychological Medicine, Monash University, Monash Medical Centre, 246 Clayton Road, Clayton, Vic. 3168, Australia (Soosai) Clayton Comm. Mental Health Service, 270 Clayton Road, Clayton, Vic. 3168, Australia (Vaddadi) Austin/Repatriation Medical Centre, Studley Road, Heidelberg, Vic. 3084, Australia
Issue Date: 17-Oct-2012
Copyright year: 2003
Publisher: Blackwell Publishing Ltd (9600 Garsington Road, Oxford OX4 2XG, United Kingdom)
Place of publication: United Kingdom
Publication information: British Journal of Clinical Pharmacology. 55 (3) (pp 307-309), 2003. Date of Publication: 01 Mar 2003.
Abstract: Aims: To compare plasma and red-cell selenium concentrations of schizophrenic patients treated with clozapine, with healthy controls and patients with mood disorders. Method(s): Plasma and red-cell selenium concentrations were measured in random venous blood samples from four groups: mood disorder (n = 36), schizophrenics treated with clozapine (n = 54), schizophrenics not treated with clozapine (n = 41) and a healthy control group (n = 56). Assays were performed by an independent laboratory that was blinded to the patient groups and specializes in estimating trace metal concentrations. Result(s): Selenium concentrations in plasma and red cells were found to be significantly lower in schizophrenic patients treated with clozapine as compared with all other groups. Conclusion(s): Selenium is an essential antioxidant. Its deficiency has been implicated in myocarditis and cardiomyopathy. Low selenium concentrations in clozapine-treated patients may be important in the pathogenesis of life threatening cardiac side-effects associated with clozapine. Further clinical studies are being conducted to explore this important clinical observation and its therapeutic implications.
DOI: http://monash.idm.oclc.org/login?url=http://dx.doi.org/10.1046/j.1365-2125.2003.01773.x
PubMed URL: 12630982 [http://www.ncbi.nlm.nih.gov/pubmed/?term=12630982]
ISSN: 0306-5251
URI: https://repository.monashhealth.org/monashhealthjspui/handle/1/32693
Type: Article
Subjects: *schizophrenia/dt [Drug Therapy]
selenium deficiency/si [Side Effect]
trace metal blood level
*clozapine/ae [Adverse Drug Reaction]
*clozapine/do [Drug Dose]
*clozapine/dt [Drug Therapy]
*clozapine/pd [Pharmacology]
*selenium/cr [Drug Concentration]
myocarditis/si [Side Effect]
adult
agranulocytosis/si [Side Effect]
article
blood sampling
cardiomyopathy/si [Side Effect]
catecholamine metabolism
dietary intake
female
human
major clinical study
male
oxidative stress
priority journal
risk benefit analysis
*schizophrenia/di [Diagnosis]
major clinical study
myocarditis / side effect
oxidative stress
priority journal
risk benefit analysis
*schizophrenia / *diagnosis / *drug therapy
selenium deficiency / side effect
adult
male
trace metal blood level
agranulocytosis / side effect
article
blood sampling
cardiomyopathy / side effect
catecholamine metabolism
dietary intake
female
human
Appears in Collections:Articles

Show full item record

Page view(s)

36
checked on Aug 17, 2024

Google ScholarTM

Check


Items in Monash Health Research Repository are protected by copyright, with all rights reserved, unless otherwise indicated.